- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
First Helium
Black Swan Graphene
Purpose Bitcoin ETF
Soma Gold Corp.
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BioHarvest Sciences
Developing Disruptive Biofarming Technology for the Cannabis Industry
Company Highlights
- Over $30 million has been invested in developing BioHarvest Sciences’ biofarming technology
- BioHarvest’s bio-superfood product VINIA® is designed to support heart health and improve blood circulation by leveraging compounds commonly found in red wine
- Biofarming technology has the potential to ease bottlenecks in the cannabis industry
- BioHarvest has already produced six unique cannabinoids in suspension: THC, CBD, THCA, CBDA, CBN and CNC
- BioHarvest Sciences intends to utilize a B2B business model, supplying its active ingredient products as a powder for repackaging by its clients.
- The current production capacity of the company’s facility is two tons per year, which the company aims to increase to ten tons per year.
- Has successfully created cannabis trichomes at the suspension phase
- BioHarvest Sciences’ seasoned management team has a track record of success
Overview
BioHarvest Sciences (CSE:BHSC), a biotechnology innovator, is targeting the international market demand for natural products that provide consumers with functional health and wellness. This includes consumer products ranging from foods enriched with active ingredients like antioxidants to cleaner and more consistent cannabis products. BioHarvest Sciences has developed biofarming, a proprietary breakthrough patented technology, capable of naturally-producing the active ingredients of a plant without having to grow the plant itself. The company has already proven the technology in the rapidly growing nutraceuticals market focusing on dietary supplements and the functional food and beverage ingredients market. Products such as BioHavest Sciences’ VINIA®, which is based on red grapes, has clinically- proven functional benefits, has already positively impacted the lives of thousands of Israelis and is approved for sale in the US.
The global cannabis market is expected to reach US$66.3 billion by the end of 2025, according to a report by Grand View Research. A large portion of the growth has been driven by the adoption of cannabis in the pharmaceutical industry as new products have been developed to treat severe medical conditions such as cancer, Parkinsons, Alzheimers and arthritis. However, issues with consistent cannabis supply can affect the long-term growth of the industry as more countries initiate cannabis programs and legislative reforms, posing potential difficulties for licensed producers to provide enough high-quality products to meet the demand.
BioHarvest Sciences Inc. believes that its biofarming technology is the solution to the cannabis supply and consistency problem. The technology isolates the active ingredient cells from the cannabis plant before multiplying (growing) them in the biofarming process. The technology can do this without using any solvent extraction, genetic modification or synthetic molecular processing techniques. To facilitate its biofarming operation, BioHarvest Sciences Inc. has built a production facility that can produce approximately one ton of active cannabis ingredient powder (equivalent to the cannabis plant dried bud) per year in a 100-square-meter space. The company intends to increase its production to 10 tons per year by 2022.
As of September 2019, the company produced its first cannabis cells in suspension with a cannabinoid profile that was identical to the original cannabis plant without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.
In December 2021, the company released the news that it has now grown a significant amount (10kg) of cannabis biomass, all grown in proprietary bioreactors and without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.
BioHarvest Sciences has already demonstrated the feasibility and viability of the biofarming technology through its commercially available product called VINIA®. In 2021, BioHarvest recorded US$2.4 million worth of sales orders for VINIA®, a nearly sixfold increase over 2020. The growth is driven by a growing customer base in Israel, and a successful ecommerce launch of VINIA® in the USA. The projected revenue this year is between US$5 million to US7 million, which represents a significant growth of 2.5X-3.5X over 2021.
VINIA® is based on many studies which have demonstrated that moderate consumption of red wine every day is able to have a positive impact on one’s overall heart health as a result of wine’s rich polyphenol content, specifically resveratrol. One 400mg capsule of VINIA® contains the same amount of resveratrol contained in one full bottle of Red Wine without the sugar, calories or alcohol found in red wine. Consumers can currently purchase the powder through the VINIA.com website in a 400-milligram daily dose after BioHarvest made it possible to also make VINIA® available online in the United States, the world's largest market for nutraceutical supplements.
At present, BioHarvest is unstoppable in disrupting industries with unique products and solutions. After VINIA®'s immense sales success, the company has trademarked its proprietary non-GMO biotech platform technology called "Bio-Plant CELLicitation™," replacing "BioFarming".
In an interview, BioHarvest CEO Ilan Sobel talked about Bio-Plant CELLicitation™, a platform technology growing plant cells in industrial-scale bioreactors and eliciting specific molecules to produce unique botanical compounds with high human utility value. Accoridng to Sobel, the unique platform technology allows them to grow full-spectrum, non-GMO cannabis.
""We can play in so many different areas, not just nutraceuticals, not just the cannabinoid space, but in many other areas where we're able to bring the power of the plant to the people," Sobel said.
Company Highlights
- Over $30 million has been invested in developing BioHarvest Sciences’ biofarming technology
- BioHarvest’s bio-superfood product VINIA® is designed to support heart health and improve blood circulation by leveraging compounds commonly found in red wine
- Biofarming technology has the potential to ease bottlenecks in the cannabis industry
- BioHarvest has already produced six unique cannabinoids in suspension: THC, CBD, THCA, CBDA, CBN and CNC
- BioHarvest Sciences intends to utilize a B2B business model, supplying its active ingredient products as a powder for repackaging by its clients.
- The current production capacity of the company’s facility is two tons per year, which the company aims to increase to ten tons per year.
- Has successfully created cannabis trichomes at the suspension phase
- BioHarvest Sciences’ seasoned management team has a track record of success
Get access to more exclusive Life Science Investing Stock profiles here
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.